Equities analysts expect that Synlogic (NASDAQ:SYBX) will report $210,000.00 in sales for the current quarter, Zacks reports. Four analysts have issued estimates for Synlogic’s earnings, with estimates ranging from $100,000.00 to $500,000.00. The business is scheduled to issue its next earnings results on Tuesday, May 8th.
According to Zacks, analysts expect that Synlogic will report full-year sales of $820,000.00 for the current fiscal year, with estimates ranging from $400,000.00 to $2.00 million. For the next financial year, analysts expect that the firm will report sales of $1.12 million per share, with estimates ranging from $400,000.00 to $3.20 million. Zacks’ sales averages are an average based on a survey of analysts that follow Synlogic.
Synlogic (NASDAQ:SYBX) last posted its quarterly earnings data on Tuesday, March 20th. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $0.07. The firm had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.11 million.
Several hedge funds have recently bought and sold shares of SYBX. Spark Investment Management LLC purchased a new stake in Synlogic during the 4th quarter worth about $105,000. Deutsche Bank AG increased its holdings in Synlogic by 204.0% during the 4th quarter. Deutsche Bank AG now owns 19,672 shares of the biotechnology company’s stock worth $190,000 after purchasing an additional 13,200 shares during the period. Renaissance Technologies LLC purchased a new stake in Synlogic during the 4th quarter worth about $191,000. Finally, Artal Group S.A. purchased a new stake in Synlogic during the 4th quarter worth about $5,335,000. Hedge funds and other institutional investors own 48.97% of the company’s stock.
SYBX stock opened at $11.46 on Friday. The company has a current ratio of 9.82, a quick ratio of 9.82 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $221.34, a P/E ratio of -1.95 and a beta of 2.22. Synlogic has a 12-month low of $8.76 and a 12-month high of $23.00.
TRADEMARK VIOLATION WARNING: “Zacks: Brokerages Anticipate Synlogic (SYBX) Will Announce Quarterly Sales of $210,000.00” was published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://dakotafinancialnews.com/2018/04/14/zacks-brokerages-anticipate-synlogic-sybx-will-announce-quarterly-sales-of-210000-00.html.
Synlogic Company Profile
Synlogic, Inc develops synthetic biotic medicines for the treatment of patients with urea cycle disorder and phenylketonuria. The company is based in Cambridge, Massachusetts.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.